Table 5.

Probability to achieve LDA at Year 1 among patients treated with certolizumab pegol (CZP) 200 mg plus methotrexate (MTX) according to baseline DAS28 > 7.48. LDA: low disease activity defined as DAS28(ESR) ≤ 3.2; n: number of patients not achieving a particular DAS28 threshold (row) up to a particular timepoint (column). Grey, white, and black shading indicate > 10%, 5%–10%, and < 5% probability of achieving LDA at 1 year, respectively. ITT: intent-to-treat.